Besifovir

CAS No. 441785-26-8

Besifovir( PMCDG Dipivoxil | ANA-380 | LB-80380 )

Catalog No. M14501 CAS No. 441785-26-8

Besifovir (PMCDG Dipivoxil, NA-380, LB-80380) is a potent, selective, orally available anti-HBV agent, the prodrug of PMCDG (EC50=4 uM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 1143 Get Quote
50MG 2322 Get Quote
100MG 3060 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Besifovir
  • Note
    Research use only, not for human use.
  • Brief Description
    Besifovir (PMCDG Dipivoxil, NA-380, LB-80380) is a potent, selective, orally available anti-HBV agent, the prodrug of PMCDG (EC50=4 uM).
  • Description
    Besifovir (PMCDG Dipivoxil, NA-380, LB-80380) is a potent, selective, orally available anti-HBV agent, the prodrug of PMCDG (EC50=4 uM).HBV Infection Phase 3 Clinical.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    PMCDG Dipivoxil | ANA-380 | LB-80380
  • Pathway
    Microbiology/Virology
  • Target
    HBV
  • Recptor
    HBV
  • Research Area
    Infection
  • Indication
    HBV Infection

Chemical Information

  • CAS Number
    441785-26-8
  • Formula Weight
    527.515
  • Molecular Formula
    C22H34N5O8P
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC(C)(C)C(=O)OCOP(=O)(COC1(CC1)CN2C=NC3=CN=C(N=C32)N)OCOC(=O)C(C)(C)C
  • Chemical Name
    [[1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Choi JR, et al. J Med Chem. 2004 May 20;47(11):2864-9. 2. Yuen MF, et al. Hepatology. 2010 Mar;51(3):767-76. 3. Papatheodoridis GV, et al. Curr Opin Mol Ther. 2006 Aug;8(4):352-7.
molnova catalog
related products
  • Lagociclovir

    Lagociclovir (MIV-210), a nucleoside analogue, is an antiviral compound available for the treatment of HBV82 that inhibits the replication of wild-type hepatitis B virus (HBV) in human hepatocellular carcinoma cell lines that permanently express HBV.

  • HBV-IN-37

    HBV-IN-37 is an HBV inhibitor with an EC50 value of 10 μM and can be used for hepatitis B disease-related research.

  • Canocapavir

    Canocapavir (ZM-H1505R) is a novel orally available HBV coat protein modulator with antiviral activity that induces conformational changes in the linker region of the HBV core protein, and can be used for the treatment of hepatitis B virus.